Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.57-0.19 (-2.81%)
At close: 04:00PM EST
6.57 0.00 (0.00%)
After hours: 05:01PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.76
Open6.67
Bid6.52 x 900
Ask6.59 x 3000
Day's range6.56 - 6.90
52-week range6.56 - 43.49
Volume530,856
Avg. volume668,172
Market cap755.55M
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-1.27
Earnings date14 Feb 2022 - 18 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.75
  • GlobeNewswire

    Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022. 40th Annual J.P. Morgan Healthcare Conference Date: Thursday, January 13th, 2022 Time:9:45am Eastern Time Webcast:The

  • GlobeNewswire

    Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

    NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that the Company achieved alignment with the FDA Division of Neurology 1 (“FDA”) to move forward in myasthenia gravis (“MG”). Immunovant plans to start its Phase 3 study for batoclimab in MG in the first half of calendar year 2022. The trial will include an induction (primary efficacy) period during

  • GlobeNewswire

    Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021. Stifel 2021 Virtual Healthcare Conference Presentation Date:Wednesday, November 17th, 2021Time: 2:00pm Eastern TimeWebcast: